FDA approval of TPOXX® as a treatment for smallpox
“The Food and Drug Administration’s (FDA) approval of TPOXX® (tecovirimat) as a treatment for smallpox marks a milestone for biosecurity and a triumph against one of the most deadly diseases in history. TPOXX®, produced by SIGA Technologies, is the first – and only—FDA-approved smallpox antiviral treatment.”
HHS partners to develop new treatment for seizures caused by nerve agents
Uncontrollable seizures are a devastating result of exposure to nerve agents. Under the BARDA contract, development of the new drug is part of ASPR’s efforts to develop medical products, procedures, and capabilities to protect health and save lives in terrorist attacks, including those using nerve agents.
HHS purchases anthrax antitoxin for Strategic National Stockpile
The Biomedical Advanced Research and Development Authority, a component of ASPR, provided funding under Project BioShield for continued manufacturing and purchase of the treatment. The product will be delivered to the Strategic National Stockpile for use in a public health emergency.
Fighting microscopic threats through international collaboration: Health ministers use lessons learned from the 1918 influenza pandemic to strengthen pandemic preparedness and global health security
The GHSI focused on the need to have a common approach to evidence based NPIs to slow the spread of flu, communication, & address public risk perception.
Contaminated Water in Flint
Flint, Michigan is facing a serious public health crisis, with high levels of lead in its water supply. HHS is committed to supporting the residents and health agencies in Flint and across Michigan.
|
|